1. Gralla RJ, Osoba D, Kris MG, Kirbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol1999;17:2971–94.
2. Miyata K, Kamato T, Nishda A, Ito H, Katsuyama Y, Iwai A, Yuki H, Yamano M, Tsutsumi R, Ohta M, et al. Pharmacologic profile of R-5-[(1-mehtyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride (YM060), a potent and selective 5-hydrotryptamine3 receptor antagonist, and its enantiomer in the isolated tissue. J Pharmacol Exp Ther1991;259:15–21.
3. Ito H, Hidaka K, Miyata K, Kamato Y, Nishida A, Honda K. Characterization of YM060, a potent and selective 5-hydroxytryptamine3 receptor antagonist, in rabbit nodose ganglion and N1E-115 neuroblastoma cells. J Pharmacol Exp Ther1992;263:1127–32.
4. Fujihara A, Tanaka S, Suzuki M, Yamamoto M, Asano M. The effect of YM060, a novel 5-HT3 receptor antagonist, on 5-HT-induced Bezold–Jarisch reflex in ferrets. Clin Rep1994;2:2329–35.
5. Fujihara A, Tanaka S, Suzuki M, Yamamoto M, Asano M. The effect of YM060, a novel 5-HT3 receptor antagonist, on cisplatin-induced emesis in ferret. Clin Rep1994;28:2337–47.